BLFS:NSD-BioLife Solutions Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 29.25

Change

-0.14 (-0.48)%

Market Cap

USD 1.28B

Volume

0.42M

Avg Analyst Target

USD 62.00 (+111.97%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BioLife Solutions Inc (BLFS) Stock Analysis:
Based on the BioLife Solutions Inc stock forecasts from 5 analysts, the average analyst target price for BioLife Solutions Inc is USD 62.00 over the next 12 months. BioLife Solutions Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioLife Solutions Inc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, BioLife Solutions Inc’s stock price was USD 29.25. BioLife Solutions Inc’s stock price has changed by -2.68% over the past week, -7.29% over the past month and -27.96% over the last year.

About

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied resear ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

-2.03 (-0.69%)

USD109.94B 66.35 56.84
HOLX Hologic Inc

+1.01 (+1.46%)

USD17.50B 9.65 7.26
MASI Masimo Corporation

-0.40 (-0.18%)

USD12.87B 57.97 49.11
XRAY DENTSPLY SIRONA Inc

-0.14 (-0.26%)

USD11.79B 28.36 14.28
RGEN Repligen Corporation

+2.97 (+1.59%)

USD10.32B 88.82 73.96
NVCR NovoCure Limited

-0.23 (-0.36%)

USD7.18B 1,480.87 4,066.85
AZTA Azenta Inc

-0.61 (-0.75%)

USD6.56B 58.97 406.97
ICUI ICU Medical Inc

-2.82 (-1.31%)

USD5.22B 43.74 18.69
STAA STAAR Surgical Company

+0.05 (+0.07%)

USD3.59B 160.83 123.68
MMSI Merit Medical Systems Inc

+0.01 (+0.02%)

USD3.26B 75.47 25.40

ETFs Containing BLFS

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.52% 19% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.52% 19% F 14% F
Trailing 12 Months  
Capital Gain -27.96% 38% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.96% 38% F 33% F
Trailing 5 Years  
Capital Gain 1,534.17% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,534.17% 100% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 119.07% 97% A+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.07% 97% A+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 124.98% 16% F 12% F
Risk Adjusted Return 95.27% 81% B- 93% A
Market Capitalization 1.28B 64% D 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 235.42 12% F 6% F
Price/Book Ratio 2.94 72% C- 41% F
Price / Cash Flow Ratio 193.29 3% F 2% F
EV/EBITDA 1,026.27 8% F 1% F
Management Effectiveness  
Return on Equity 1.39% 58% F 53% F
Return on Invested Capital -0.05% 53% F 51% F
Return on Assets -2.48% 43% F 39% F
Debt to Equity Ratio 0.32% 90% A- 89% B+
Technical Ratios  
Short Ratio 3.44 39% F 34% F
Short Percent 5.48% 25% F 30% F
Beta 1.60 26% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.